American Society of Hematology

News

ASH: Jaypirca matches Imbruvica in first-line CLL trial

Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.

News

ASH: Gilead preps filing for anito-cel on iMMagine-1 data

Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.

News

ASH: AstraZeneca's dual-wielding CAR-T shows promise

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.

Partner Content

Partner Content

pharmaphorum and Symplur launch Conference360 Report

pharmaphorum media and Symplur, LLC launch Conference360 Report to help pharma and other stakeholders understand social media conversations around medical congresses

ASH: Jaypirca matches Imbruvica in first-line CLL trial

ASH: Gilead preps filing for anito-cel on iMMagine-1 data

ASH: AstraZeneca's dual-wielding CAR-T shows promise

pharmaphorum and Symplur launch Conference360 Report

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

American Society of Hematology

Editor's Picks